News and Events
News
Press release 08.26.2008 - Semafore Broadens Pipeline with Multi-Targeted Kinase Inhibitors
Press release 08.26.2008 - SF1126, Semafore's PI3 Kinase Inhibitor, Found To Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
06.04.2008 - Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
Events
02.13.2008 - BIO CEO & Investor Conference 2008: On February 13th Semafore's CEO Ed Jacobs will present at 2:45 pm (ET) at the Waldorf-Astoria in the Park Avenue Suite
04.04.2006 - Identification of Molecular Markers for Selection of Patients Likely to Respond and Pharmacodynamic Markers of Delivery of Biologically Relevant Dose and Early Response to a Novel Phosphatidylinositol 3-kinase PI3K Inhibitory Prodrug, SF1126
04.04.2006 - In Vitro and In Vivo Preclinical Studies on the Novel PI3 Kinase Inhibitor SF1126
|